Apellis Pharmaceuticals, Inc.·4

Jan 14, 4:15 PM ET

Eisele Jeffrey 4

4 · Apellis Pharmaceuticals, Inc. · Filed Jan 14, 2025

Insider Transaction Report

Form 4
Period: 2025-01-13
Eisele Jeffrey
Chief Development Officer
Transactions
  • Sale

    Common Stock

    2025-01-13$28.70/sh264$7,57756,881 total
Footnotes (1)
  • [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 10, 2025.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT